Clinical trials: Clear Cell Renal Cell Carcinoma Metastatic
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Metastatic Renal Cell Carcinoma
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
The primary objective of this study is to evaluate the incidence of high-grade (i.e. Grade 3-4 and Grade 5 of CTCAE v4.0) adverse reactions of interest in patients with metastatic RCC who have progressed during or after receiving…
- Trial name
- NIVOREN (NCT03013335)
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 730 people
- Sponsor
- UNICANCER
Metastatic Renal Cell Carcinoma
A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
The primary objective of this study is to answer the question "Is it possible to inject the Combig-DC vaccine in a renal tumour without getting unacceptable side effects"? Patients newly diagnosed with metastatic renal cell…
- Trial name
- NCT01525017
- Testing
- Combig-DC (allogeneic dendritic cells) Cancer Vaccine
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Mendus
Metastatic Clear Cell Renal Cell Carcinoma
CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
The purpose of this study is to evaluate the safety and feasibility of a treatment holiday strategy directed by CD70-targeted immuno-PET/CT in patients with metastatic clear cell renal cell carcinoma (mccRCC).
- Trial name
- PERFUMER-70 (NCT07615348)
- Testing
- PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause
- Where
- 5 sites in China
- Volunteers
- 75 people
- Sponsor
- Jinling Hospital, China
Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
The purpose of this study is to evaluate whether Time Restricted Eating (TRE) can improve responses in participants with metastatic head and neck squamous cell cancer (mHNSCC) or unresectable/metastatic renal cell carcinoma (RCC)…
- Conditions
- Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT06603155
- Testing
- Time restricted eating (TRE)
- Where
- United States
- Sponsor
- Duke University
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT07128680
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Renal Cell
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to…
- Trial name
- ATILA (NCT03916458)
- Where
- 31 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Pfizer